Drugs

Journal Metrics
(Based on the publications from the last 4 years)
(from 2022-01-01 to roughly 2026-01-01)
Number of papers600
H4-Index58
TQCC26
Average citations22.223
Median citations10
Impact Factor14.400 (based on Web of Science 2024)
Twitter@DrugsJournal (ca. 298 followers)

(API-Link)

Categories & Ranks
Metric:
(Based on the publications from the last 4 years)
Most cited by this journal
(Based on citations to the other journals in the most recent 30 papers in this journal, at least if metadata about citations were available; last updated 2025-08-16)
Impactful Papers
(Based on publications since 2023; last updated 2025-10-30)
Altmetric Attention Score: 436
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase
Drugs 2025-10-03
Altmetric Attention Score: 156
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation
Drugs 2023-03-17
Altmetric Attention Score: 41
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-
Drugs 2024-06-21
Altmetric Attention Score: 41
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramipr
Drugs 2024-06-21
Altmetric Attention Score: 39
Sipavibart: First Approval
Drugs 2025-06-13
Ad
0.0041401386260986